BioNTech expects Omicron-adapted vaccine deliveries as soon as October

Pending regulatory approval, both vaccines would be supplied in time for booster campaigns come autumn, said the company. Second-quarter revenue and net profit both dropped by around 40% compared with the same period a year ago, at 3.2 billion euros ($3.26 billion) and 1.672 billion euros, respectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hNCoFtf
via IFTTT